Aura Biosciences Stock (NASDAQ:AURA)

Forecast Ownership Financials Chart

Previous Close

$7.06

52W Range

$4.34 - $12.38

50D Avg

$6.34

200D Avg

$7.52

Market Cap

$448.29M

Avg Vol (3M)

$213.40K

Beta

0.45

Div Yield

AURA Company Profile

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

106

IPO Date

Oct 29, 2021

Website

AURA Performance

AURA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	-	$-84.99M	$-60.30M
Net Income	$-86.92M	$-76.41M	$-57.23M
EBITDA	-	$-83.70M	$-59.12M
Basic EPS	$-1.75	$-1.93	$-1.91
Diluted EPS	$-1.75	$-1.93	$-1.91

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
MLYS	Mineralys Therapeutics, Inc.
JBIO	Jade Biosciences, Inc.
ANEB	Anebulo Pharmaceuticals, Inc.
ADAG	Adagene Inc.
BCYC	Bicycle Therapeutics plc
TYRA	Tyra Biosciences, Inc.
XLO	Xilio Therapeutics, Inc.
BCAB	BioAtla, Inc.
EWTX	Edgewise Therapeutics, Inc.
TRDA	Entrada Therapeutics, Inc.